Global Information
회사소개 | 문의 | 비교리스트

프로테이나제 K 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년)

Proteinase K Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2022년 01월 상품코드 995770
페이지 정보 영문 배송안내 2-3일 (영업일 기준)
US $ 4,750 ₩ 6,306,000 PDF & Excel (Single User License)
US $ 5,250 ₩ 6,970,000 PDF & Excel (Team License: Up to 7 Users)
US $ 6,500 ₩ 8,630,000 PDF & Excel (Site License)
US $ 8,750 ₩ 11,617,000 PDF & Excel (Corporate License)

프로테이나제 K 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년) Proteinase K Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
발행일 : 2022년 01월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 프로테이나제 K 시장 규모는 예측기간 중 약 3%의 CAGR로 확대될 것으로 예측됩니다.

만성 질환이나 감염증 부담 증대, 진단 기술과 그와 관련된 IVD 효소 응용 확대는 시장 성장을 촉진할 것으로 예상되는 중요한 동향입니다.

프로테이나제 K는 COVID-19의 검출에 큰 가능성을 잠재하고 있습니다. 이것은 시장에 성장의 길을 열 것으로 기대되고 있습니다. 2020년 12월에 발표된 "SARS-CoV-2 RNA의 신속하고 편리하고 효율적인 키트에 의존하지 않는 검출"이라는 타이틀의 연구에 의하면 94.6%의 민감도로 단순한 프로테이나제 K 처리와 반복 가열 스텝이 키트 기반 분리 방법과 비교되었습니다. 프로테이나제 K법은 SARS-CoV-2 RNA를 추출하기 위한 편리하고 효율적인 방법으로 간주된다고 판명되었습니다.

만성 질환은 세계에서 가장 만연하고 있는 건강 상태입니다. 만성 질환에는 암, 당뇨병, 고혈압, 뇌졸중, 심장병, 호흡기질환, 관절염, 비만 등이 있으며, 입원, 장기적인 장애, 삶의 질 저하, 나아가 사망으로 이어집니다. GLOBOCAN 2020에 의하면 암의 5년 이환수는 세계에서 약 50,550,287명이라고 보고되었으며, 암에 의한 사망자수는 세계에서 약 9,958,133명으로 기록되고 있습니다. 암 유병률 상승은 차세대 시퀀싱 및 중합효소 연쇄 반응 응용 확대로 이어지고 있습니다.

또한 연구개발 활동 증가와 연구기관, 제약회사, 바이오의약품 기업에 의한 혁신에 대한 투자가 시장 성장을 지지하고 있습니다. 그러나 DNA 정제를 위한 새로운 첨단 기술이 이용 가능하다는 점이 프로테이나제 K 시장 성장을 저해할 것으로 보입니다.

세계의 프로테이나제 K(Proteinase K) 시장에 대해 조사했으며, 시장 개요와 함께 형태별, 치료 분야별, 지역별 동향 및 시장에 참여하는 기업 개요 등을 제공합니다.


제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 추진력
    • 만성 및 감염증 부담 증가
    • IVD를 위한 진단 기술과 그와 관련된 효소의 응용 확대
  • 시장 성장 억제요인
    • DNA 정제를 위한 새로운 세련된 기술 이용 가능성
  • Porter's Five Force 분석

제5장 시장 세분화

  • 형태별
    • 분말
    • 액체
  • 치료 분야별
    • 감염증
    • 당뇨병
    • 종양학
    • 심장병학
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 기타 지역

제6장 경쟁 상황

  • 기업 개요
    • Merck KGaA
    • F. Hoffmann-La Roche Ltd.
    • Advanced Enzymes Technologies
    • Biocatalysts Ltd.
    • Thermo Fisher Scientific
    • Klee GmbH
    • Dyadic International
    • QIAGEN
    • Cell Signalling Technology Inc.
    • Danaher Corporation(Leica Biosystems)
    • Geno Technology Inc.(G Bioscience)?
    • Amicogen
    • A & A Biotechnology
    • bioWORLD
    • New England Biolabs
    • Promega Corporation,
    • Avantor

제7장 시장 기회와 동향

KSM 21.03.22

The proteinase K market is expected to register a CAGR of nearly 3% during the forecast period, 2021-2026. The rising burden of chronic disorders and infectious diseases and growing applications of diagnostic techniques and their associated enzymes for IVD​ are among key trends that are expected to trigger the market growth.

Proteinase K has a great potential in the detection of COVID-19, which is also anticipated to provide growth avenues to the market. As per a study titled, "Rapid, convenient and efficient kit-independent detection of SARS-CoV-2 RNA", published in December 2020, simple proteinase K treatment and repetitive heating steps with a sensitivity of 94.6% were compared with kit-based isolation methods. It was found out that the proteinase K method can be considered as a convenient and efficient method for extraction of SARS-CoV-2 RNA.

Chronic diseases are the most prevalent health condition globally. Chronic diseases include cancer, diabetes, hypertension, stroke, heart disease, respiratory diseases, arthritis, and obesity, which lead to hospitalization, long-term disability, reduced quality of life, and even death.​ According to the GLOBOCAN 2020, the 5-year prevalence for cancer was reported to be around 50,550,287 worldwide, and about 9,958,133 deaths due to cancer were recorded globally. The rising prevalence of cancer has led to an increase in next-generation sequencing and polymerase chain reaction applications. ​

Furthermore, the increasing research and development activities and investments by research institutes and pharmaceutical and biopharmaceutical companies in innovation help the market to grow. However, the availability of new sophisticated technologies for DNA purification may hamper the growth of the proteinase K market.

Key Market Trends

The Infectious Diseases Segment is Expected to Dominate the Market Over the Forecast Period

The infectious diseases segment is found to dominate the proteinase K market that has been attributed to the increasing prevalence of infectious diseases and the wide applicability of proteinase K in the diagnosis of various infectious diseases.

With the rising COVID-19 cases, there is wide adoption of the enzyme in COVID-19 diagnostics, which is expected to contribute to the dominant share of the segment throughout the forecast period.

There is also a rising number of infectious diseases that have helped in boosting the overall market growth. For instance, as per the Global Tuberculosis (TB) Report 2019, the incidence of TB in low-income regions was higher during 2018, whereas in the developed regions, it was comparatively low. The report has also suggested that the incidence of TB in Africa was around 2,450,000, whereas, in the Americas, it was around 289,000.​

According to the World Health Organization 2019 Report, there is also a high burden of infectious diseases, including HIV, TB, malaria, hepatitis B, and neglected tropical diseases, that are found to be higher in low-income countries compared to the high-income countries. Globally, in 2017, the incidence rate of new HIV infections was 1.09 times higher in men than in women.

Moreover, several studies show that incubation of DNA for the hepatitis B virus with proteinase K results in efficient DNA isolation. The DNA yield from this proteinase K is being increased by 5 times compared to standard procedures that do not require proteinase K. Thus, the wide applicability of proteinase K in the diagnosis of several infectious diseases is a key factor that helps the market grow.

North America Represents the Largest Market During the Forecast Period

North America is found registering high growth in the region due to the increasing number of cancer and infectious diseases and growing next-generation sequencing and polymerase chain reaction applications that are found boosting the market growth in the region. This is expected to drive the demand for proteinase K required in NGS and PCR techniques.

Moreover, with the emergence of COVID-19, the use of proteinase K registered increased, and therefore, new products were developed, which impacted the market positively. For instance, in May 2020, Zymo research received an Emergency Use Authorization by the United States Food & Drug Administration for "Quick SARS-CoV-2 rRT-PCR Kit" that includes "Proteinase K w/ Storage Buffer set". Such product approvals are expected to boost the demand for proteinase K.

According to the United States' National Center for Health Statistics, chronic diseases affect approximately 133 million Americans, representing more than 40% of the total population of the country, and by 2020, it is projected to grow to an estimated 157 million, with 81 million having multiple conditions.

According to the Centers for Disease Control and Prevention's (CDC) 2018 report on "Disease rates and the number of new cases", the number of new cases and rate of many infectious diseases have increased in the recent decades. The number of new cases of Acute hepatitis A, B, and C viral infection was 1670, 3374, and 849 in 2010, respectively. The data reports that the number of new cases increased to 3365, 3409, and 4225 in 2017, respectively.

According to the Pharmaceutical Research and Manufacturers Association (PhRMA), 2018, US firms conduct over half the world's R&D in pharmaceuticals. Approximately 79.6 billion was invested in biopharmaceutical research and development in the United States in 2018. Therefore, all these factors are found creating high growth opportunities for proteinase K in the North American region.

Competitive Landscape

The proteinase K market is moderately competitive and few of the major players are currently dominating the market. Some of the companies currently dominating the market are Merck KGaA, F. Hoffmann-La Roche Ltd, Advanced Enzyme Technologies, Biocatalysts, Thermo Fisher Scientific, Klee GmbH, Dyadic International, and QIAGEN. The key players in the market are involved in novel product launches, acquisitions, collaborations, partnerships, and geographical expansions to reinforce their market presence.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Chronic and Infectious Diseases
    • 4.2.2 Growing Applications of Diagnostic Techniques and their Associated Enzymes for IVD​
  • 4.3 Market Restraints
    • 4.3.1 Availability of New Sophisticated Technologies for DNA Purification
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Form
    • 5.1.1 Powder
    • 5.1.2 Liquid
  • 5.2 By Therapeutic Area
    • 5.2.1 Infectious Diseases
    • 5.2.2 Diabetes
    • 5.2.3 Oncology
    • 5.2.4 Cardiology
    • 5.2.5 Other Therapeutic Areas
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Rest of the World


  • 6.1 Company Profiles
    • 6.1.1 Merck KGaA
    • 6.1.2 F. Hoffmann-La Roche Ltd
    • 6.1.3 Advanced Enzymes Technologies
    • 6.1.4 Biocatalysts Ltd
    • 6.1.5 Thermo Fisher Scientific
    • 6.1.6 Klee GmbH
    • 6.1.7 Dyadic International
    • 6.1.8 QIAGEN
    • 6.1.9 Cell Signalling Technology Inc.
    • 6.1.10 Danaher Corporation (Leica Biosystems)
    • 6.1.11 Geno Technology Inc. (G Bioscience)​
    • 6.1.12 Amicogen
    • 6.1.13 A & A Biotechnology
    • 6.1.14 bioWORLD
    • 6.1.15 New England Biolabs
    • 6.1.16 Promega Corporation
    • 6.1.17 Avantor


Back to Top
전화 문의